Developer docs
API playgroundTry for free, no card

Search company profiles

Neuronetics

Full company profile

uuid0002dmw

Namestring
Neuronetics
Legal namestring
Neuronetics, Inc.
Websiteurl
neuronetics.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

Neuronetics is a publicly traded medical device company (NASDAQ:STIM) founded in 2003 and headquartered in Malvern, Pennsylvania, that develops and commercializes the NeuroStar Advanced Therapy System, a non-invasive transcranial magnetic stimulation (TMS) platform used primarily to treat major depressive disorder in patients who have not responded to antidepressant medication. The NeuroStar system delivers targeted magnetic pulses to mood-regulation areas of the brain and is integrated with ANT Neuro's FDA-cleared visor2 neuronavigation system for real-time spatial tracking and 3D visualization. The company reports clinical outcomes including an 83% response rate and a 62% remission rate across more than 175,000 patients treated, and the system is covered by major insurers including TRICARE, Optum, and United Healthcare.

In December 2024 Neuronetics completed the all-stock acquisition of Greenbrook TMS Inc., creating a vertically integrated organization that combines device manufacturing with company-operated and partner-operated treatment centers across the United States. Revenue is generated through three streams: NeuroStar system sales to healthcare providers (34 systems shipped in Q1 2026, up 10% YoY), treatment session revenue from Greenbrook centers ($9.1M in Q1 2026), and clinic operations revenue ($21.5M in Q1 2026, up 15% YoY). Distribution is domestic-only and conducted via direct enterprise field sales to hospitals, psychiatric practices, and mental health clinics. Coverage has expanded to approximately 34.8 million commercial lives following the Optum/UHC/UBH partnership.

Neuronetics generates meaningful top-line scale ($149.2M in FY2025, up 99% YoY largely on the Greenbrook acquisition) but remains unprofitable at the GAAP level, with FY2025 EBITDA of $-27.6M and net income of $-39.0M, though Q4 2025 produced $0.9M of positive operating cash flow. The company entered 2026 with approximately $34.1M in cash, a new CEO (Dan Reuvers, former CEO of Tactile Medical), an interim CFO following Steven Pfanstiel's May 2026 departure, and an active Board-level evaluation of separating the NeuroStar and Greenbrook businesses — moves driven in part by activist shareholder Jorey Chernett, who holds approximately 10% of outstanding shares and is advocating for strategic alternatives including a potential sale.

Short descriptiontext

Neuronetics (NASDAQ:STIM) is a Malvern, PA-based medical device company that develops and sells the NeuroStar TMS platform for treatment-resistant depression and operates Greenbrook TMS treatment centers across the United States following its December 2024 acquisition.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMalvern, United States
HQ citystring
Malvern
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcranial magnetic stimulation, TMS therapy systems, neuromodulation devices, depression treatment devices, psychiatric medical devices
Industry1 code
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Outpatient Mental Health and Substance Abuse Centers621420
  • Offices of Physicians, Mental Health Specialists621112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Health Services8000
Product category
Neuromodulation Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1NeuroStar System Sales
TypeHardware Sales
Description

Sale of NeuroStar Advanced Therapy TMS systems to healthcare providers and clinics. Revenue from system shipments increased 13% year-over-year with 34 systems shipped in Q1 2026.

globenewswire.com
2Treatment Session Revenue
TypeUsage Based
Description

Revenue generated from TMS treatment sessions administered at Greenbrook TMS treatment centers. Treatment session revenue was $9.1 million in Q1 2026.

fool.com
3Clinic Operations Revenue
TypeManaged Services
Description

Revenue from operating Greenbrook TMS treatment centers across the United States. U.S. clinic revenue grew 15% to $21.5 million in Q1 2026 following the acquisition of Greenbrook TMS.

bizjournals.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NeuroStar Advanced Therapy System
Description

FDA-cleared transcranial magnetic stimulation (TMS) platform for treating mental health conditions including depression

globenewswire.com
Core offering1 text field

Neuronetics designs, manufactures, and sells the NeuroStar Advanced Therapy System, a non-invasive transcranial magnetic stimulation (TMS) device for treating major depressive disorder in patients who have not responded to antidepressant medications. The company also operates Greenbrook TMS treatment centers across the United States, providing in-clinic TMS therapy services to patients. Following the December 2024 acquisition of Greenbrook TMS, the company is now vertically integrated across device manufacturing and clinical service delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 83% response rate for depression treatment
+3 more records
Product overview1 text field

Neuronetics operates as a vertically integrated organization in the transcranial magnetic stimulation (TMS) market. The company offers two main product lines: the NeuroStar Advanced Therapy System (the core TMS technology platform) and Greenbrook TMS treatment centers (clinic operations acquired in December 2024). Together, these enable end-to-end TMS treatment delivery from device provision to patient care.

Product and service2 records
1NeuroStar Advanced Therapy System
CategoryNeuromodulation Medical Device (TMS System)
Description

Non-invasive transcranial magnetic stimulation (TMS) treatment system for mental health disorders, particularly major depressive disorder in patients who have not responded to medication. The system delivers magnetic pulses to stimulate specific areas of the brain associated with mood regulation, and has been used to treat over 175,000 patients with an 83% response rate and 62% remission rate for depression.

2Greenbrook TMS Treatment Centers
CategoryClinical Treatment Services
Description

Network of TMS treatment centers across the United States acquired through the all-stock acquisition of Greenbrook TMS Inc. in December 2024. Patients receive TMS therapy treatments using the NeuroStar system at these company-operated clinic locations, generating treatment session revenue. U.S. clinic revenue reached $21.5 million in Q1 2026, up 15% year-over-year.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-14
Description

Strategic preferred partnership to integrate ANT Neuro's FDA-cleared visor2 neuronavigation system with the NeuroStar Advanced Therapy TMS platform. The collaboration enables healthcare providers to incorporate real-time spatial tracking and 3D visualization into transcranial magnetic stimulation treatments. Broader rollout planned for second half of 2026 following showcases at APA Annual Meeting and Clinical TMS Society Annual Meeting.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

Three-year exclusive partnership for NeuroStar TMS device provision across 30+ clinic locations in Florida and Virginia. Collaboration includes expanded patient support services using Greenbrook platform capabilities including PHQ-10 processing, TMS consultations, and scheduling. Partnership launched as pilot in Q4 2025 with expansion planned for 2026.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Denmark-based developer and manufacturer of TMS and rTMS systems for research and clinical use, including depression treatment. Competes with NeuroStar in the TMS device market for psychiatric care.

TypeEmerging player
Description

Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Represents a potential future alternative modality to TMS for the same TRD patient population NeuroStar serves.

TypeBroad incumbent
Description

Global medical device leader with extensive neuromodulation portfolio including deep brain stimulation (DBS), spinal cord stimulation, and brain-computer-interface investments. Adjacent competitor to NeuroStar in device-based psychiatric and neurological therapy.

TypeBroad incumbent
Description

Commercial-stage biopharmaceutical company with Auvelity, an FDA-approved NMDA receptor antagonist for major depressive disorder. Competes with NeuroStar in the treatment-resistant depression market via an alternative (pharmaceutical) mechanism.

TypeDirect peer
Description

Israel-based medical device company that develops Deep Transcranial Magnetic Stimulation (Deep TMS) systems for depression, OCD, and other psychiatric disorders. Most direct head-to-head competitor to NeuroStar in FDA-cleared TMS therapy for treatment-resistant depression.

TypeBroad incumbent
Description

Biopharmaceutical company with FDA-approved neuroactive steroid therapies (Zurzuvae for postpartum depression, Zulresso). Competes with NeuroStar for depression patient share, particularly in severe and treatment-resistant populations.

7Magstim
TypeDirect peer
Description

UK-based manufacturer of transcranial magnetic stimulation systems used in clinical research and depression treatment. Direct competitor to NeuroStar in TMS hardware for psychiatric and neurological applications.

TypeDirect peer
Description

US-based developer of transcranial direct current stimulation (tDCS) and TMS devices for depression, anxiety, and insomnia. Competes with NeuroStar in the office-based neurostimulation market for behavioral health treatment.

TypeBroad incumbent
Description

Diversified medical device leader with a significant neuromodulation franchise (spinal cord stimulation, deep brain stimulation, dorsal root ganglion stimulation). Competes with NeuroStar in device-based neurotherapy and broader neuromodulation markets.

TypeBroad incumbent
Description

Through its Janssen pharma division, markets Spravato (esketamine nasal spray), an FDA-approved treatment for treatment-resistant depression. Direct alternative to NeuroStar for severe, refractory depression patients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuronetics

Neuromodulation Medical Devicesneuronetics.com

Neuronetics (NASDAQ:STIM) is a Malvern, PA-based medical device company that develops and sells the NeuroStar TMS platform for treatment-resistant depression and operates Greenbrook TMS treatment centers across the United States following its December 2024 acquisition.

What Neuronetics does

Neuronetics is a publicly traded medical device company (NASDAQ:STIM) founded in 2003 and headquartered in Malvern, Pennsylvania, that develops and commercializes the NeuroStar Advanced Therapy System, a non-invasive transcranial magnetic stimulation (TMS) platform used primarily to treat major depressive disorder in patients who have not responded to antidepressant medication. The NeuroStar system delivers targeted magnetic pulses to mood-regulation areas of the brain and is integrated with ANT Neuro's FDA-cleared visor2 neuronavigation system for real-time spatial tracking and 3D visualization. The company reports clinical outcomes including an 83% response rate and a 62% remission rate across more than 175,000 patients treated, and the system is covered by major insurers including TRICARE, Optum, and United Healthcare.

In December 2024 Neuronetics completed the all-stock acquisition of Greenbrook TMS Inc., creating a vertically integrated organization that combines device manufacturing with company-operated and partner-operated treatment centers across the United States. Revenue is generated through three streams: NeuroStar system sales to healthcare providers (34 systems shipped in Q1 2026, up 10% YoY), treatment session revenue from Greenbrook centers ($9.1M in Q1 2026), and clinic operations revenue ($21.5M in Q1 2026, up 15% YoY). Distribution is domestic-only and conducted via direct enterprise field sales to hospitals, psychiatric practices, and mental health clinics. Coverage has expanded to approximately 34.8 million commercial lives following the Optum/UHC/UBH partnership.

Neuronetics generates meaningful top-line scale ($149.2M in FY2025, up 99% YoY largely on the Greenbrook acquisition) but remains unprofitable at the GAAP level, with FY2025 EBITDA of $-27.6M and net income of $-39.0M, though Q4 2025 produced $0.9M of positive operating cash flow. The company entered 2026 with approximately $34.1M in cash, a new CEO (Dan Reuvers, former CEO of Tactile Medical), an interim CFO following Steven Pfanstiel's May 2026 departure, and an active Board-level evaluation of separating the NeuroStar and Greenbrook businesses — moves driven in part by activist shareholder Jorey Chernett, who holds approximately 10% of outstanding shares and is advocating for strategic alternatives including a potential sale.

Neuronetics firmographics

Firmographics
Name
Neuronetics
Legal name
Neuronetics, Inc.
Website
https://neuronetics.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
Neuronetics (NASDAQ:STIM) is a Malvern, PA-based medical device company that develops and sells the NeuroStar TMS platform for treatment-resistant depression and operates Greenbrook TMS treatment centers across the United States following its December 2024 acquisition.
Ownership category
akta.pro rank

Neuronetics industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Transcranial magnetic stimulation
  • TMS therapy systems
  • Neuromodulation devices
  • Depression treatment devices
  • Psychiatric medical devices

Where Neuronetics is headquartered

Location

Headquarters

HQ city
Malvern
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Neuronetics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. NeuroStar System Sales: Sale of NeuroStar Advanced Therapy TMS systems to healthcare providers and clinics. Revenue from system shipments increased 13% year-over-year with 34 systems shipped in Q1 2026.
  2. Treatment Session Revenue: Revenue generated from TMS treatment sessions administered at Greenbrook TMS treatment centers. Treatment session revenue was $9.1 million in Q1 2026.
  3. Clinic Operations Revenue: Revenue from operating Greenbrook TMS treatment centers across the United States. U.S. clinic revenue grew 15% to $21.5 million in Q1 2026 following the acquisition of Greenbrook TMS.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Neuronetics product offering

Product offering

Core offering

Neuronetics designs, manufactures, and sells the NeuroStar Advanced Therapy System, a non-invasive transcranial magnetic stimulation (TMS) device for treating major depressive disorder in patients who have not responded to antidepressant medications. The company also operates Greenbrook TMS treatment centers across the United States, providing in-clinic TMS therapy services to patients. Following the December 2024 acquisition of Greenbrook TMS, the company is now vertically integrated across device manufacturing and clinical service delivery.

Product overview

Neuronetics operates as a vertically integrated organization in the transcranial magnetic stimulation (TMS) market. The company offers two main product lines: the NeuroStar Advanced Therapy System (the core TMS technology platform) and Greenbrook TMS treatment centers (clinic operations acquired in December 2024). Together, these enable end-to-end TMS treatment delivery from device provision to patient care.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroStar Advanced Therapy System: FDA-cleared transcranial magnetic stimulation (TMS) platform for treating mental health conditions including depression

Products and services

  • NeuroStar Advanced Therapy System Non-invasive transcranial magnetic stimulation (TMS) treatment system for mental health disorders, particularly major depressive disorder in patients who have not responded to medication. The system delivers magnetic pulses to stimulate specific areas of the brain associated with mood regulation, and has been used to treat over 175,000 patients with an 83% response rate and 62% remission rate for depression.
  • Greenbrook TMS Treatment Centers Network of TMS treatment centers across the United States acquired through the all-stock acquisition of Greenbrook TMS Inc. in December 2024. Patients receive TMS therapy treatments using the NeuroStar system at these company-operated clinic locations, generating treatment session revenue. U.S. clinic revenue reached $21.5 million in Q1 2026, up 15% year-over-year.

Quantifiable outcome

  • 83% response rate for depression treatment
  • +3 more outcomes

Companies that use Neuronetics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Neuronetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature2 records

Neuronetics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • ANT NeurocoreTechnology or Integration · 14 May 2026Strategic preferred partnership to integrate ANT Neuro's FDA-cleared visor2 neuronavigation system with the NeuroStar Advanced Therapy TMS platform. The collaboration enables healthcare providers to incorporate real-time spatial tracking and 3D visualization into transcranial magnetic stimulation treatments. Broader rollout planned for second half of 2026 following showcases at APA Annual Meeting and Clinical TMS Society Annual Meeting.
  • Elite DNA Behavioral HealthcoreStrategic or Co-development Partner · 30 October 2025Three-year exclusive partnership for NeuroStar TMS device provision across 30+ clinic locations in Florida and Virginia. Collaboration includes expanded patient support services using Greenbrook platform capabilities including PHQ-10 processing, TMS consultations, and scheduling. Partnership launched as pilot in Q4 2025 with expansion planned for 2026.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Neuronetics competitors and assessment

Company assessment

Direct peers

  • MagVenture: Denmark-based developer and manufacturer of TMS and rTMS systems for research and clinical use, including depression treatment. Competes with NeuroStar in the TMS device market for psychiatric care.
  • BrainsWay: Israel-based medical device company that develops Deep Transcranial Magnetic Stimulation (Deep TMS) systems for depression, OCD, and other psychiatric disorders. Most direct head-to-head competitor to NeuroStar in FDA-cleared TMS therapy for treatment-resistant depression.
  • Magstim: UK-based manufacturer of transcranial magnetic stimulation systems used in clinical research and depression treatment. Direct competitor to NeuroStar in TMS hardware for psychiatric and neurological applications.
  • Fisher Wallace: US-based developer of transcranial direct current stimulation (tDCS) and TMS devices for depression, anxiety, and insomnia. Competes with NeuroStar in the office-based neurostimulation market for behavioral health treatment.

Emerging players

  • Compass Pathways: Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Represents a potential future alternative modality to TMS for the same TRD patient population NeuroStar serves.

Broad incumbents

  • Medtronic: Global medical device leader with extensive neuromodulation portfolio including deep brain stimulation (DBS), spinal cord stimulation, and brain-computer-interface investments. Adjacent competitor to NeuroStar in device-based psychiatric and neurological therapy.
  • Axsome Therapeutics: Commercial-stage biopharmaceutical company with Auvelity, an FDA-approved NMDA receptor antagonist for major depressive disorder. Competes with NeuroStar in the treatment-resistant depression market via an alternative (pharmaceutical) mechanism.
  • Sage Therapeutics: Biopharmaceutical company with FDA-approved neuroactive steroid therapies (Zurzuvae for postpartum depression, Zulresso). Competes with NeuroStar for depression patient share, particularly in severe and treatment-resistant populations.
  • Abbott: Diversified medical device leader with a significant neuromodulation franchise (spinal cord stimulation, deep brain stimulation, dorsal root ganglion stimulation). Competes with NeuroStar in device-based neurotherapy and broader neuromodulation markets.
  • Johnson & Johnson (Janssen): Through its Janssen pharma division, markets Spravato (esketamine nasal spray), an FDA-approved treatment for treatment-resistant depression. Direct alternative to NeuroStar for severe, refractory depression patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Neuronetics social profiles

Digital presence

Neuronetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuronetics leadership team

Management profile

Number of profiles

Profiles9 records

Neuronetics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Neuronetics funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuronetics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuronetics

What does Neuronetics do?

Neuronetics designs, manufactures, and sells the NeuroStar Advanced Therapy System, a non-invasive transcranial magnetic stimulation (TMS) device for treating major depressive disorder in patients who have not responded to antidepressant medications. The company also operates Greenbrook TMS treatment centers across the United States, providing in-clinic TMS therapy services to patients. Following the December 2024 acquisition of Greenbrook TMS, the company is now vertically integrated across device manufacturing and clinical service delivery.

Is Neuronetics a public or private company?

Neuronetics is a public company. It is classified as public and is currently operating.

When was Neuronetics founded?

Neuronetics was founded in 2003. It employs 51 to 100 people.

Where is Neuronetics based?

Neuronetics is headquartered in Malvern, United States, in the North America region.

How does Neuronetics make money?

Three revenue lines are on record. NeuroStar System Sales are the primary driver. The others are treatment Session Revenue and clinic Operations Revenue.

Who are Neuronetics's main competitors?

Direct peers on record are MagVenture, BrainsWay, Magstim and Fisher Wallace. Compass Pathways is listed as an emerging player. Broad incumbents are Medtronic, Axsome Therapeutics, Sage Therapeutics, Abbott and Johnson & Johnson (Janssen).

Does Neuronetics have an API?

No public API is recorded for Neuronetics.

What industry is Neuronetics in?

Neuronetics's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewWilliam Blair initiates coverage of Neuronetics at OutperformWilliam Blair initiated coverage of Neuronetics at an Outperform rating. The analyst's price target and ratings are available on the Forecasts tab, with previous and future recommendations tracked in the News Flow.American Banking and Market NewsComparing Neuronetics (NASDAQ:STIM) and Utah Medical Products (NASDAQ:UTMD)Neuronetics and Utah Medical Products are compared on valuation, profitability, and analyst ratings. Utah Medical Products beats Neuronetics on 8 of 14 factors, including higher net margin and earnings. Neuronetics has a higher consensus price target and lower P/E, but Utah Medical Products has stronger profitability.MarketWatchNeuronetics Stock Declines on Underwritten Public Offering Aimed at Resolving Going Concern RiskNeuronetics announced an underwritten public offering expected to generate about $30 million in gross proceeds to repay debt and resolve going concern risk. Shares fell 14% to $1.73 in premarket trading. The offering is expected to close on or about Nov. 12.Seeking AlphaNeuronetics prices $30M public offering, shares slide 13% (STIM:NASDAQ)Neuronetics priced a public offering of 18.75 million shares at $1.60 each, expecting to raise about $30 million in gross proceeds before expenses. The company granted underwriters a 30-day option period, and shares fell 13% in extended trading on Wednesday.The future of tradingNeuronetics Prices $30 Million Public Offering at $1.60 a ShareNeuronetics priced an underwritten public offering of 18.75 million common shares at $1.60 each, targeting about $30 million in gross proceeds. Underwriters received a 30-day option to buy up to 2.8125 million additional shares, and the offering is expected to close on November 12, 2026. Net proceeds will partly repay the Perceptive term loan, with remaining funds for general corporate purposes.Investing.comNeuronetics launches stock offering to refinance debtNeuronetics Inc. commenced an underwritten public offering of common stock, with William Blair as lead bookrunner. The company also amended its credit agreement to reduce revenue covenants, subject to a $15 million prepayment, which would resolve going-concern risk if conditions are met by November 30, 2026.American Banking and Market NewsAnalyzing Neuronetics (NASDAQ:STIM) & Sysmex (OTCMKTS:SSMXY)Sysmex and Neuronetics are compared on valuation, earnings, and analyst ratings. Sysmex has higher revenue and earnings, but Neuronetics trades at a lower P/E and has a stronger consensus rating with a $5.00 target price implying 132.56% upside.TradingViewB. Riley Securities maintains Neuronetics at Buy, raises price target to $6 from $5B. Riley Securities maintained Neuronetics at Buy and raised its price target to $6 from $5, a 20% increase. The target implies 146.9% upside from the Nov 5 close of $2.43.Simply Wall StNeuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.75Neuronetics reported Q4 revenue of $42m, 3.8% above forecasts, and statutory losses of $0.02 per share, 3.8% lower than expected. Analysts raised the price target to $5.75, but consensus forecasts 2027 revenue of $177m and losses of $0.28 per share, implying growth at the industry pace.The future of tradingNeuronetics Grants Restricted Stock Units to 14 Non-Executive EmployeesNeuronetics granted 123,300 restricted stock units to 14 non-executive employees under its 2020 Inducement Incentive Plan. Allison Manzer received 44,250 units and Erin DiMarco received 23,250 units. Most awards vest in equal installments on the first three anniversaries of the grant date.